Hormonal Implants - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The hormonal implants market size is expected to grow from USD 0.86 billion in 2025 to USD 0.91 billion in 2026 and is forecast to reach USD 1.25 billion by 2031 at 6.49% CAGR over 2026-2031. This report is Segmented by Product Type (Etonogestrel, Levonorgestrel, Other), Application (Contraception, HRT, Menstrual Regulation, Other), End User (Hospitals, Gynecology Clinics, Health Centers, Others), Distribution Channel (Public Procurement, Private Healthcare, Retail), Geography (North America, Europe, Asia-Pacific, MEA, S. America). The Market Forecasts are Provided in Terms of Value (USD).

Global Hormonal Implants Market Trends and Insights

Rising Preference for Long-Acting Reversible Contraception

The hormonal implants market benefits from a strong clinical value proposition, as implants provide high real-world effectiveness and remove the adherence burden linked to daily methods. The CDC reported in 2025 that implants and IUDs together accounted for 10.5% of contraceptive use among U.S. women aged 15 to 49, with adoption highest among women aged 20 to 29 at 13.8%.

FP2030 reported in 2025 that implants were the most common contraceptive method in 13 countries and the second most common method in 17 others, indicating broader adoption across public health systems. A 2025 article available through PMC also highlighted a sustained rise in LARC uptake across surveyed populations, reinforcing the market’s long-term demand potential.

Expansion of Postpartum and Post-Abortion Family Planning Programs

The hormonal implants market is gaining momentum as healthcare systems integrate contraceptive access into delivery and post-procedure care pathways. A 2025 study published through PMC found that structured hospital-based postpartum family planning programs increased postpartum LARC insertions within 60 days of delivery by 11.7 percentage points in early-adopting sites. UNFPA reported that postpartum family planning indicators were embedded into national health information systems across 54 countries in 2024, enabling governments to monitor uptake and support continued funding. These pathways improve completion rates for implant insertion and expand access to clinically suitable patients beyond standalone outpatient visits.

Dependence on Reimbursement, Procurement, and Policy Coverage

The hormonal implants market remains sensitive to financing decisions, as product access often depends on reimbursement rules, public tenders, and policy continuity. CHAI reported that Zambia experienced a major supply disruption in March 2025, with Jadelle availability declining to 34% facility availability in Lusaka Province after USAID withdrew funding. Such disruptions are significant because, in many low-income settings, the hormonal implants market cannot quickly replace donor-supported supply through private distribution. In the United States, the transition to the NEXPLANON REMS program also created a temporary access risk, as clinics that did not complete certification could not order or dispense the device after the compliance deadline. Smaller suppliers also face a higher compliance burden when reimbursement and regulatory standards change simultaneously. As a result, the hormonal implants market can grow on strong demand fundamentals while still facing interruptions when funding or policy mechanisms shift too quickly.

Other drivers and restraints analyzed in the detailed report include:

• Extended Product Duration and Label Updates Supporting Replacement Cycles
• Wider Access Through Public Procurement and Donor-Funded Supply Chains
• Provider Training Requirements for Insertion and Removal

Segment Analysis

Etonogestrel implants accounted for 45.65% of the hormonal implants market size in 2025, keeping them in the lead across product categories. Their single-rod format reduced insertion complexity by requiring only one placement site and a preloaded applicator. This simpler procedure supported provider efficiency in consultations and insertions, with less room for technique variation than older multi-rod systems. The January 2026 FDA label extension for NEXPLANON from three years to five years further strengthened this position by improving the cost per protected year and supporting payer confidence.

Levonorgestrel implants were the fastest-growing product segment, with an 8.93% CAGR through 2031, supported by strong public sector demand and wider use in cost-sensitive tenders. The July 2026 Apollo investment in Bayer’s LARC business, which includes Jadelle, and the portfolio’s 12.5% growth in 2025 reinforced confidence in this segment of the hormonal implants market. Competition in this tier also broadened, as WHO-prequalified two-rod products were well-positioned in large-volume procurement programs.

Contraception held 38.23% of revenue in 2025, making it the largest application base in the hormonal implants market. This position reflected its established use in both reimbursed private systems and donor-supported public programs. UNFPA reported that implants represented 19% of the contraceptive method mix across 54 partner countries in 2024, while FP2030 reported in 2025 that implants were the leading method in 13 countries. This broad base gave the hormonal implants market a stable volume foundation, even when replacement timing changed.

Menstrual regulation and other therapeutic uses also became more visible, as clinicians increasingly recognized hormonal effects that could reduce bleeding in selected users. Hormone replacement therapy was the fastest-growing application in the hormonal implants market, with a projected 9.67% CAGR through 2031. This segment gained interest because subcutaneous estradiol pellets could provide steadier hormone levels over several months and avoid first-pass liver metabolism, strengthening the clinical case for selected patients.

Complete Report Scope:

• By Product Type
  • Etonogestrel Implants
  • Levonorgestrel Implants
  • Other Hormonal Implants
• By Application
  • Contraception
  • Hormone Replacement Therapy
  • Menstrual Regulation
  • Other Therapeutic Applications
• By End User
  • Hospitals
  • Gynecology and Fertility Clinics
  • Community Health Centers
  • Ambulatory Surgical Centers
  • Other End Users
• By Distribution Channel
  • Public Procurement
  • Private Healthcare Procurement
  • Retail and Pharmacy Channel
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 38.56% of the hormonal implants market share in 2025, keeping it ahead of every other region by revenue. The United States supported this position through higher per-unit pricing, broad reimbursement, and a large provider base experienced in implant counseling and insertion. The January 2026 NEXPLANON label extension strengthened product value in North America, although the REMS transition may have temporarily limited ordering at clinics that did not complete certification on time. Europe remained the second-largest regional block, supported by reimbursement systems in Germany, France, and the United Kingdom, while the United Kingdom’s 2026 approval of a 5-year NEXPLANON duration supported cost-effectiveness and improved value per patient.

The Asia-Pacific hormonal implants market size is projected to expand at an 8.56% CAGR through 2031, making it the fastest-growing regional market. India illustrated the regional growth pattern, as the national family planning scale-up broadened the delivery footprint for Implanon NXT and linked growth to public health access programs. In Indonesia, the REACH project launched in June 2026 through UNFPA, Organon, and public sector partners to support more equitable family planning access and stronger domestic financing foundations. Higher-income Asian markets, such as Japan, South Korea, China, and Australia, also added a second layer of opportunity as HRT and other non-contraceptive uses started gaining attention in the hormonal implants market.

The Middle East and Africa and South America were smaller than North America and Europe by revenue in 2025, but they remained important volume growth corridors in the hormonal implants market. Sub-Saharan Africa remained especially important, as large public procurement programs drove method uptake, although tighter pricing and supply interruptions had a stronger effect on access. CHAI’s 2025 findings from Zambia showed how quickly availability could decline when donor-backed supply weakened, highlighting the need for dual sourcing and stronger national buffers. South America stood out as Brazil’s public system sharply expanded implant access, creating a clear example of large-scale national procurement and service rollout.

List of Companies Covered in this Report:

• Abbvie
• Amneal Pharmaceuticals
• Aspen Pharmacare
• Bayer
• Besins Healthcare
• Zydus Group
• DKT International
• Exeltis
• FHI 360
• Gedeon Richter Plc.
• HRA Pharma
• Laboratoire HRA Pharma
• Medicines360
• Merck
• Mithra Pharmaceuticals
• Mylan
• Organon
• Organon International
• Pfizer
• Population Council
• Shanghai Dahua Pharmaceutical
• Teva Pharmaceutical Industries
• TherapeuticsMD, Inc.
• Viatris

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support